Bionatura
Bionatura
Latin American Journal of Biotechnology and Life Sciences
Latin American Journal of Biotechnology and Life Sciences
Go to content
2021.06.03.26
Files > Volume 6 > Vol 6 No 3 2021
REPORTE DE CASOS / CASE REPORTS
Previous/ Index /Next

Common Peroneal Nerve Injury in a Patient with COVID-19 Infection
 
 

Zeynab Bossaghzadeh 1, Firoozeh Niazvand 2,*, Medi Saneie 3, Shahram Rahimi-Dehgolan 4, Hooshan Sahariati Ghadikolaei 5,  Sara Mobarak6
Available from: http://dx.doi.org/10.21931/RB/2021.06.03.26
 
 

 
ABSTRACT

 
This report described a 46-year man with the characteristic Computerized Tomography (CT) scan findings of Corona Virus Disease Infection 19 (COVID-19) who presented to the hospital with right ankle weakness three weeks after the pneumonitis. He had been initially hospitalized, complaining of fever, myalgia, cough, and dyspnea. Electromyogram (EMG) revealed obvious evidence of increased insertional activity (IA) and significant denervation potentials, including positive sharp waves (PSW) and fibrillation potentials, particularly in ankle dorsiflexor muscles. Moreover, no voluntary motor unit action potential (MUAP) was observed. Eventually, the patient was diagnosed with severe axonal mononeuropathy of the right CPN, which could be considered a rare complication of COVID-19.
 
Keywords: Nerve injury; Electromyography; Coronavirus; COVID-19.

 
 
INTRODUCTION

 
A new beta coronavirus named COVID-19 was detected in December 2019 in Wuhan City, China, and shortly became a pandemic1. COVID-19 is fused with the angiotensin-converting enzyme II (ACE-II) receptor and enters the cells2. This new coronavirus can cause several systemic infections, among which respiratory complications are the most prevalent, quite similar to what earlier happened in severe acute respiratory syndrome coronavirus called SARS-CoV 3.
 
It has been previously proved that around one-third of patients with COVID-19 had neurological symptoms. Although several specific neurological presentations such as anosmia, other non-specific ones, including reduced consciousness level, dizziness, and headache, have also been detected4. In one study, 214 patients with COVID-19 were evaluated in terms of neurological symptoms5. According to their findings, 36.4% of the hospitalized patients showed nervous system manifestations such as hyposmia, hypogeusia, headache, muscle injury, dizziness, ischemic, and hemorrhage stroke. However, it is still unknown whether the neurological symptoms are associated with the virus's direct damage, an abnormal immune response, or secondary mechanisms, including systemic inflammation or multi-organ dysfunction.
 
It has been hypothesized that SARS-CoV-2 can be considered as a new neuropathogen. However, it has not yet been proven by solid evidence [6]. Before COVID-19, it had been well-defined that infectious peripheral neuropathy could happen secondary to other viruses, including varicella-zoster, hepatitis C and human immunodeficiency virus (HIV)7. Similarly, during a viral infection, immune-mediated neuropathies such as chronic inflammatory demyelinating polyneuropathy (CIDP), as well as Guillain-Barre syndrome (GBS), might occur8. Also, an extended stay in the hospital can cause peripheral nerves.
 
Damage resulting from prolonged pressure effect or even critical illness polyneuropathy9. Recently, in some case reports, a potential relationship between peripheral nerve injury and the SARS-CoV-2 infection preceding the onset of damage by up to 4 weeks. Thus, the most probable reason would be a SARS-CoV2-triggered dysregulation of the immune system10-12. This case report described a male patient infected with COVID-19 who showed a common peroneal nerve (CPN) injury as a rare complication.

 
 
CASE PRESENTATION

 
On 2 December, 2020, a 46-year-old man complained of inability to dorsiflex the right ankle from 3 weeks ago. The patient has referred to the emergency ward about 6 weeks ago under the probable diagnosis of COVID-19 and symptoms including fever, body aches, cough, and shortness of breath. During hospitalization, the polymerase chain reaction (PCR) and computerized chest tomography (CT) scan were performed and confirmed the diagnosis (Figure 1).


 
 
Figure 1. Findings of the CT scan of COVID-19 patient. Bilateral  peripheral  ground-glass  opacities  in a patient with cough and dyspnea

 
The patient had been admitted for 2 weeks resulting in 20 kg weight loss during this period. One week after the patient came back home, he noticed paresthesia on the right foot's dorsum and the sudden weakness of the right ankle dorsiflexion while walking and during the affected limb's swing phase.
 
He was referred to the clinic of physical medicine and rehabilitation (PM&R) to perform electromyography (EMG) and nerve conduction studies (NCS). As a result, sensory nerve action potential (SNAP) of the right superficial peroneal nerve (SPN) was not present, and the compound muscle action potential (CMAP) of the deep peroneal nerve (DPN) nerve was absent at the right side. In the EMG analysis, some evidence of increased insertional activity (IA) and denervation potentials, including PSW and fibrillation potentials, were detected in Tibialis Anterior (TA), Peroneus Longus (PL), Extensor Hallucis Longus (EHL), and Extensor Digitorum Brevis (EDB) muscles. Moreover, no voluntary motor unit action potential (MUAP) was observed in these muscles. Therefore, he was diagnosed with severe acute mono-neuropathy of the right CPN. Lumbosacral spine magnetic resonance imaging (MRI) was performed to assess discopathy, which was reported to be expected.

 
DISCUSSION

As we mentioned, as a post-infectious inflammatory response after SARS-CoV-2 infection, peripheral nerve injury can occur during the acute phase of resolution. This might be either the result of an abnormal hyper-immune response or treatment complications for COVID-19, such as nerve entrapment secondary to hematoma in the anticoagulation consumption setting or prolonged hospitalization that could be positional or critical illness-related polyneuropathy.
 
In the presented case, the patient was diagnosed with severe mononeuropathy of the right CPN after 3 weeks of developing symptoms such as fever, body aches, cough, and shortness of breath; compatible with COVID-19 pneumonia. The possibility of a direct neuropathic effect or an abnormal hyper-immune response in COVID-19 patients requires further research. There have been existed several case reports about GBS incidence among COVID-19 sufferers10, 13, 16.
 
This case has been reported even though all neurological manifestations in severe COVID-19 are not fully understood yet; then, the peripheral neuropathic damage cannot be positively attributed to COVID-19 due to the lack of nerve biopsy. However, the EMG findings, along with the clinical neural image, indicated peripheral neuropathy. There are two main probabilities in this regard: 1) direct involvement of nerve by the virus and the following inflammatory response; 2) nerve compression after severe weight loss has also been reported in bariatric surgery and so on17, 18.
 
On the other hand, it has not clearly been understood how weight loss contributes to peroneal neuropathy. It is assumed that changes in metabolism followed by weight loss and mechanical compression of the peroneal nerve can play a significant role in this regard17, 21. The adipose tissue depletion (inside and surrounding the nerve) results from weight loss; thus, the peroneal nerve's sensitivity to compression caused by the PL tendon on the lateral side and the adjacent fibular head medial side increases22.
 
The ACE-II receptor is where COVID-19 and SARS have in common19. The receptor is found in the cell membrane of various organs in humans, such as the liver, kidney, lung, skeletal muscle, and nervous system5. However, the mechanisms involved in peripheral nerve injury incidence after COVID-19 infection have not yet been precisely studied. COVID-19 stimulates inflammatory cells, and different cytokines are generated, resulting in immune-mediated processes19. Therefore, peripheral nerve injury after SARS-CoV-2 infection is a theoretical consideration, and some COVID-19 patients have been reported to present with peripheral neuropathy and GBS13, 20. Then, the cases of immune-mediated nerve injuries should be considered during this pandemic. According to the global pandemic of the SARS-COVID-1923-26, additional surveys should be conducted to find all epidemiological properties of disease27.

 
 
CONCLUSION

 
To summarize, peripheral nerve injury should always be considered as a neurological complication that might occur in COVID-19. Probable post-infection peripheral nerve injury mechanisms include autoimmune response, direct neuro-invasion by the virus, and systemic disease complications. Further investigations are necessary to shed light on the exact pathophysiology of peripheral nerve involvement and high-risk patient determination. Given that, clinicians must be aware of these relationships to prevent delayed diagnosis from promoting treatment initiation at early stages and supportive care. This fact will be elucidated by further identified cases as well as longer time results.

 
 
Acknowledgments
 
The authors would like to thank the School of Medicine, Abadan Faculty of Medical Sciences, Abadan, Iran, for the clinical supports.

 
 
Author contributions
 
FN designed the study and carried out the case identification. ZB, MS, and SRD carried out the CT-Scan and PCR. HSG and SM carried out the history taking and electromyography. FN wrote and drafted the manuscript. All authors read and confirm the final manuscript.
 
 
Competing interests
 
The authors declared that they have no conflict of interest.
 
 
Data and materials availability
 
All data are available in the main text or supplementary materials.
 
 
Ethics statement
 
As noted on the journal's author guidelines page, the authors confirm that the journal's ethical policies have been adhered to. All identifying information of the patient presented in this study was kept secret.

 
 
REFERENCES

 
[1] Zhu N, Zhang D, Wang W. China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019 [published 24 January, 2020]. N Engl J Med.
 
[2] Wan Y, Shang J, Graham R, Baric RS, Li F. Information: read & look at all below. 2020.
 
[3] Zhou P, Lou YX, Wang X, Hu B, Zhang L, Zhang W. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature [Internet]. 2020; 579 (7798): 270–3.
 
[4] Zito A, Alfonsi E, Franciotta D, Todisco M, Gastaldi M, Cotta Ramusino M, et al. COVID-19 and Guillain-Barré Syndrome: A Case Report and Review of Literature. Front Neurol. 2020;11:909-.
 
[5] Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA neurology. 2020;77:683-90.
 
[6] Fernandez CE, Franz CK, Ko JH, Walter JM, Koralnik IJ, Ahlawat S, et al. Imaging Review of Peripheral Nerve Injuries in Patients with COVID-19. Radiology. 2020:203116.
 
[7] Sindic CJ. Infectious neuropathies. Current opinion in neurology. 2013;26:510-5.
 
[8] Katona I, Weis J. Diseases of the peripheral nerves.  Handbook of clinical Neurology: Elsevier; 2018. p. 453-74.
 
[9] Tsivgoulis G, Palaiodimou L, Katsanos AH, Caso V, Köhrmann M, Molina C, et al. <? covid19?> Neurological manifestations and implications of COVID-19 pandemic. Therapeutic Advances in Neurological Disorders. 2020;13:1756286420932036.
 
[10] Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, et al. Guillain–Barré syndrome associated with SARS-CoV-2. New England Journal of Medicine. 2020.
 
[11] Bigaut K, Mallaret M, Baloglu S, Nemoz B, Morand P, Baicry F, et al. Guillain-Barré syndrome related to SARS-CoV-2 infection. Neurology-Neuroimmunology Neuroinflammation. 2020;7.
 
[12] Farzi MA, Ayromlou H, Jahanbakhsh N, Bavil PH, Janzadeh A, Shayan FK. Guillain-Barré syndrome in a patient infected with SARS-CoV-2, a case report. Journal of neuroimmunology. 2020;346:577294.
 
[13] Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? The Lancet Neurology. 2020;19:383-4.
 
[14] Sedaghat Z, Karimi N. Guillain Barre syndrome associated with COVID-19 infection: a case report. Journal of Clinical Neuroscience. 2020.
 
[15] Virani A, Rabold E, Hanson T, Haag A, Elrufay R, Cheema T, et al. Guillain-Barré syndrome associated with SARS-CoV-2 infection. IDCases. 2020:e00771.
 
[16] Webb S, Wallace VC, Martin-Lopez D, Yogarajah M. Guillain-Barré syndrome following COVID-19: a newly emerging post-infectious complication. BMJ Case Reports CP. 2020;13:e236182.
 
[17] Thaisetthawatkul P, Collazo-Clavell M, Sarr M, Norell J, Dyck PJB. A controlled study of peripheral neuropathy after bariatric surgery. Neurology. 2004;63:1462-70.
 
[18] Clark N. Neuropathy following bariatric surgery.  Seminars in neurology: © Thieme Medical Publishers; 2010. p. 433-5.
 
[19] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020;395:497-506.
 
[20] Abdelnour L, Abdalla ME, Babiker S. COVID 19 infection presenting as motor peripheral neuropathy. Journal of the Formosan Medical Association. 2020.
 
[21] Sernik RA, Abicalaf CA, Pimentel BF, Braga-Baiak A, Braga L, Cerri GG. Ultrasound features of carpal tunnel syndrome: a prospective case-control study. Skeletal radiology. 2008;37:49-53.
 
[22] Meylaerts L, Cardinaels E, Vandevenne J, Velghe B, Gelin G, Vanormelingen L, et al. Peroneal neuropathy after weight loss: a high-resolution ultrasonographic characterization of the common peroneal nerve. Skeletal radiology. 2011;40:1557-62.
 
[23] Ranjbar R, Mahmoodzadeh Hosseini H, Safarpoor Dehkordi F. A Review on Biochemical and Immunological Biomarkers used for Laboratory Diagnosis of SARS-CoV-2 (COVID-19). The Open Microbiology Journal. 2020;14(1).
 
[24] Mirzaie A, Halaji M, Dehkordi FS, Ranjbar R, Noorbazargan H. A narrative literature review on traditional medicine options for treatment of corona virus disease 2019 (COVID-19). Complementary Therapies in Clinical Practice. 2020:101214.
 
[25] Halaji M, Farahani A, Ranjbar R, Heiat M, Dehkordi FS. Emerging coronaviruses: first SARS, second MERS and third SARS-CoV-2: epidemiological updates of COVID-19. Infez Med. 2020;28(suppl 1):6-17.
 
[26] Sheikhshahrokh A, Ranjbar R, Saeidi E, Dehkordi FS, Heiat M, Ghasemi-Dehkordi P, Goodarzi H. Frontier therapeutics and vaccine strategies for sars-cov-2 (COVID-19): A review. Iranian Journal of Public Health. 2020;49:18-29.
 
[27] Dehkordi FS, Valizadeh Y, Birgani TA, Dehkordi KG. Prevalence study of Brucella melitensis and Brucella abortus in cow's milk using dot enzyme linked immuno sorbent assay and duplex polymerase chain reaction. J Pure Appl Microbiol. 2014;8(2):1065-9.

 
 
Received: 20 April 2021
 
Accepted: 10 June 2021
 
 
 
Zeynab Bossaghzadeh 1, Firoozeh Niazvand 2,*, Medi Saneie 3, Shahram Rahimi-Dehgolan 4, Hooshan Sahariati Ghadikolaei 5,  Sara Mobarak6
 
1Assistant professor of Physical Medicine, Rehabilitation and Electrodiagnosis Department, School of Medicine Abadan Faculty of Medical Sciences, Abadan, Iran.
 
2Assistant Professor of Anatomical Science, School of Medicine, Abadan Faculty of Medical Sciences, Abadan, Iran.
 
3Department of Orthopedics, School of Medicine, Abadan Faculty of Medical Sciences.
 
4PM&R Department, Tehran University of Medical Sciences, Tehran, Iran.
 
5Department of Neurosurgery, School of Medicine, Abadan Faculty of Medical Sciences, Abadan, Iran.
 
6Assistant Professor of Infectious Disease, School of Medicine, Abadan Faculty of Medical Sciences, Abadan, Iran.
 
*Corresponding author: Dr. Niazvand Firoozeh., Assistant Professor of Anatomical Science, School of Medicine, Abadan Faculty of Medical Sciences, Abadan, Iran. Email address: .
 
Back to content